What is HER2?

Human epidermal growth factor receptor 2, or HER2, receptors are found on the surface of cells, including healthy cells and cancer cells. Part of their job in the body is telling cells to grow and divide.

HER2+ breast cancer cells have more HER2 receptors than normal. Too many HER2 receptors make these cancer cells grow and divide too rapidly, causing tumors to form.

What is targeted cancer therapy?

Targeted cancer treatments are designed to attack specific proteins on certain types of cancer cells that cause them to grow and multiply rapidly. Because these proteins are found on normal cells as well, targeted treatments can also affect healthy cells.

PERJETA and Herceptin target cells with too much HER2

PERJETA is given with another targeted treatment called Herceptin. Both treatments are designed to fight cancer cells that have too many HER2 receptors, but in different ways. Since normal cells also have HER2 receptors (just not as many), PERJETA and Herceptin can also affect healthy cells. These treatments may cause side effects, including serious side effects. See Important Safety Information below.

PERJETA is thought to block one of the methods of signaling so that certain receptors are unable to pair with HER2. PERJETA and Herceptin work on different parts of the HER2 receptor, so they work together to build a stronger blockade. Because normal cells also have some HER2 receptors, targeted therapies may also affect them.

Understand the potential benefits and possible risks of PERJETA + Herceptin-based therapy in early breast cancer (EBC)

Understand the potential benefits and possible risks of PERJETA+ Herceptin and docetaxel in metastatic breast cancer (MBC)